Genocea's mission is to conquer cancer by developing personalized cancer immunotherapies in multiple tumor types. Our unique ATLAS™ platform comprehensively profiles each patient's T cell responses to potential targets, or antigens, on the tumor. ATLAS enables us to optimize the neoantigens for inclusion in our immunotherapies and exclude inhibitory antigens, Inhibigens™, that can exert an immunosuppressive effect. We are advancing two ATLAS-enabled programs: GEN-009, our neoantigen vaccine and GEN-011, our neoantigen-specific cell therapy using T cells derived from peripheral blood.
Company profile
Ticker
GNCAQ, GNCAQ
Exchange
Website
CEO
William Clark
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
Former names
GENOCEA BIOSCIENCES INC
SEC CIK
GNCAQ stock data
Latest filings (excl ownership)
15-12B
Securities registration termination
13 Jun 22
EFFECT
Notice of effectiveness
13 Jun 22
EFFECT
Notice of effectiveness
13 Jun 22
POS AM
Prospectus update (post-effective amendment)
9 Jun 22
POS AM
Prospectus update (post-effective amendment)
9 Jun 22
EFFECT
Notice of effectiveness
8 Jun 22
EFFECT
Notice of effectiveness
8 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
S-8 POS
Registration of securities for employees (post-effective amendment)
3 Jun 22
Transcripts
GNCAQ
Earnings call transcript
2021 Q4
10 Mar 22
GNCAQ
Earnings call transcript
2021 Q3
28 Oct 21
GNCAQ
Earnings call transcript
2021 Q2
29 Jul 21
GNCAQ
Earnings call transcript
2021 Q1
29 Apr 21
GNCAQ
Earnings call transcript
2020 Q4
11 Feb 21
GNCAQ
Earnings call transcript
2020 Q3
29 Oct 20
GNCAQ
Earnings call transcript
2020 Q2
23 Jul 20
GNCAQ
Earnings call transcript
2020 Q1
30 Apr 20
GNCAQ
Earnings call transcript
2019 Q4
13 Feb 20
GNCAQ
Earnings call transcript
2019 Q3
28 Oct 19
Latest ownership filings
4
Diantha Duvall
3 Jun 22
4
Jessica Baker Flechtner
3 Jun 22
4
William D Clark
3 Jun 22
4
JACQUELYN L SUMER
2 Jun 22
4
William D Clark
2 Jun 22
4
George Siber
1 Jun 22
SC 13D/A
New Enterprise Associates 16, L.P.
27 May 22
4
Paul Edward Walker
26 May 22
4
Peter W. Sonsini
26 May 22
4
SCOTT D SANDELL
26 May 22
Financial summary
Quarter (USD) | Mar 22 | Dec 21 | Sep 21 | Jun 21 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 21 | Dec 20 | Dec 19 | Dec 18 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm | 20.77 mm |
Cash burn (monthly) | 5.67 mm | 3.82 mm | 5.26 mm | 4.62 mm | 5.07 mm | 4.02 mm |
Cash used (since last report) | 139.51 mm | 94.10 mm | 129.36 mm | 113.68 mm | 124.73 mm | 98.79 mm |
Cash remaining | -118.74 mm | -73.34 mm | -108.59 mm | -92.91 mm | -103.96 mm | -78.03 mm |
Runway (months of cash) | -20.9 | -19.2 | -20.7 | -20.1 | -20.5 | -19.4 |
Institutional ownership, Q2 2023
47.3% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 4 |
Opened positions | 0 |
Closed positions | 0 |
Increased positions | 0 |
Reduced positions | 0 |
13F shares | Current |
---|---|
Total value | 84.16 mm |
Total shares | 27.81 mm |
Total puts | 0.00 |
Total calls | 0.00 |
Total put/call ratio | – |
Largest owners | Shares | Value |
---|---|---|
New Enterprise Associates 16 | 15.40 mm | $69.00 mm |
Biotechnology Value Fund L P | 5.93 mm | $6.88 mm |
GSK GSK | 5.86 mm | $6.80 mm |
Vivo Opportunity | 613.44 k | $1.49 mm |